<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Three-hundred fifty-one women were referred for <z:mp ids='MP_0005048'>thrombosis</z:mp> and hemostasis evaluation after suffering <z:e sem="disease" ids="C0000809" disease_type="Disease or Syndrome" abbrv="">recurrent miscarriages</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were referred by a high-risk obstetrician or reproductive medicine specialist after anatomic, hormonal or chromosomal defects had been ruled out </plain></SENT>
<SENT sid="2" pm="."><plain>These patients were assessed over a three year period </plain></SENT>
<SENT sid="3" pm="."><plain>The mean patient age at referral was 34 years and the mean number of <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriages</z:e> was 2.9 (2-9) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients underwent a thorough evaluation for <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> and, when indicated, a <z:e sem="disease" ids="C0019087" disease_type="Disease or Syndrome" abbrv="">hemorrhagic disorder</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Of the 351 patients, 29 (8%) had no defect </plain></SENT>
<SENT sid="6" pm="."><plain>Of the remaining 322 patients, 7 (2%) had a <z:mp ids='MP_0001914'>bleeding</z:mp> disorder: 3 with platelet dysfunction, 1 with <z:e sem="disease" ids="C0015530" disease_type="Disease or Syndrome" abbrv="">Factor XIII deficiency</z:e>, 3 with <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e>'s and 3 with Osler-Weber-Rendu </plain></SENT>
<SENT sid="7" pm="."><plain>The remainder of the patients had a <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> as follows: 195 (60%) had <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, 64 (20%) had Sticky Platelet Syndrome, 38 (12%) had MTHFR mutation, 23 (7.1%) had PAI-1 polymorphism, 12 (3.7%) had <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">Protein S deficiency</z:e>, 12 (3.7%) had Factor V Leiden, 3 (1%), had AT deficiency, 3 (1%) had <z:chebi fb="5" ids="28304">Heparin</z:chebi>-Cofactor II deficiency, 3 (1%) had <z:chebi fb="6" ids="15702,53394">TPA</z:chebi> deficiency, and 6 (2%) had <z:hpo ids='HP_0005543'>Protein C deficiency</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>There were a total of 364 defects found in the 312 patients harboring <z:hpo ids='HP_0100724'>thrombophilia</z:hpo>; thus, several harbored two and a few harbored three separate defects </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients with <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> were treated with preconception <z:chebi fb="37" ids="15365">ASA</z:chebi> at 81 mg/day with the immediate post-conception addition of <z:chebi fb="5" ids="28304">heparin</z:chebi> or LMW <z:chebi fb="5" ids="28304">heparin</z:chebi> (Dalteparin) </plain></SENT>
<SENT sid="10" pm="."><plain>Both <z:chebi fb="37" ids="15365">ASA</z:chebi> and <z:chebi fb="5" ids="28304">heparin</z:chebi>/LMW <z:chebi fb="5" ids="28304">heparin</z:chebi> were used to term </plain></SENT>
<SENT sid="11" pm="."><plain>The first 120 patients were treated with unfractionated <z:chebi fb="5" ids="28304">heparin</z:chebi> at 5,000 U every 24 hours, subcutaneously and the last 192 have been treated with Dalteparin at 5,000 U/day subcutaneously </plain></SENT>
<SENT sid="12" pm="."><plain>The patients with MTHFR were also treated with <z:chebi fb="3" ids="37445">folate</z:chebi> at 5 mg/day + <z:chebi fb="5" ids="16709">pyridoxine</z:chebi> at 50 mg/day </plain></SENT>
<SENT sid="13" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were carefully monitored with CBC and platelet counts, anti-Xa levels, frequent ultrasounds and <z:e sem="disease" ids="C0034065,C0031809" disease_type="Health Care Activity;Disease or Syndrome" abbrv="">physical exams</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>Only 2 of the <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> patients suffered another <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriage</z:e>; <z:hpo ids='HP_0000001'>all</z:hpo> others had a <z:mpath ids='MPATH_458'>normal</z:mpath> term delivery </plain></SENT>
<SENT sid="15" pm="."><plain>There were no pregnancy-related thromboses, no delivery complications and no episodes of post-partum <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="16" pm="."><plain>The only <z:mp ids='MP_0001914'>bleeding</z:mp> consisted of 1-4 cm <z:mp ids='MP_0009275'>bruises</z:mp> at injection sites </plain></SENT>
<SENT sid="17" pm="."><plain>No episodes of <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (HIT) were noted </plain></SENT>
<SENT sid="18" pm="."><plain>In our experience, <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> is a common cause of <z:e sem="disease" ids="C0000809" disease_type="Disease or Syndrome" abbrv="">recurrent miscarriage</z:e> and <z:hpo ids='HP_0000001'>all</z:hpo> patients with no anatomical, hormonal or chromosomal defect should be evaluated for <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> or a <z:mp ids='MP_0001914'>bleeding</z:mp> disorder </plain></SENT>
<SENT sid="19" pm="."><plain>The success rate of <z:mpath ids='MPATH_458'>normal</z:mpath> term delivery in these 312 patients was 94% using <z:chebi fb="37" ids="15365">ASA</z:chebi> + <z:chebi fb="5" ids="28304">heparin</z:chebi> or Dalteparin </plain></SENT>
<SENT sid="20" pm="."><plain>In addition, side effects of therapy were minimal </plain></SENT>
</text></document>